AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Sionna Therapeutics, Inc.

$7.85 -$31.36 (-79.98%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$7.62
Day Range
$7.47$8.03
Year Range
$4.01$54.97
Market Cap
354.43M
AVG Volume
1.46M
Trailing/Forward PE
-3.6/-
PEG ratio
-3.58
Dividend Yield
-
Next Earnings Date
2026-11-04
Primary Exchange
NASDAQUS
Net Income (USD)
-80M-60M-40M-20M020242025
SION Net Income (USD) by year
PeriodNet Income (USD)
2025-75.27M
2024-61.69M
Operating Income (USD)
-100M-75M-50M-25M020242025
SION Operating Income (USD) by year
PeriodOperating Income (USD)
2025-88.98M
2024-70.56M
EBITDA (USD)
-80M-60M-40M-20M020242025
SION EBITDA (USD) by year
PeriodEBITDA (USD)
2025-70.49M
2024-60.82M
Cash Flows (USD)
-80M-60M-40M-20M020242025
SION Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-66.67M
2024-52.81M
EPS (USD)
-2-1.5-1-0.5020242025
SION EPS (USD) by year
PeriodEPS (USD)
2025-1.7
2024-1.4
Expenses (USD)
025M50M75M100MR&DSG&ACapex20242025
SION Expenses (USD) by year
PeriodExpenses (USD)
202589.84M
202470.81M
Cash & Debt (USD)
0100M200M300M20242025
SION Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025235.88M
2024147.54M
Debt ratios
024620242025
SION Debt ratios by year
PeriodDebt ratios
20254.99
20243.63
Return on Capital
-40%-20%0%20%40%20242025
SION Return on Capital by year
PeriodReturn on Capital
2025-24.53%
202437.68%
Shares Outstanding
020M40M60M20242025
SION Shares Outstanding by year
PeriodShares Outstanding
202539.96M
202444.12M
Book Value Per Share (USD)
-5051020242025
SION Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20257.68
2024-3.71
Total Assets (USD)
0100M200M300M400M20242025
SION Total Assets (USD) by year
PeriodTotal Assets (USD)
2025325.95M
2024185.75M
Employee Count
020406020242025
SION Employee Count by year
PeriodEmployee Count
202559
202441
Free Cash Flow Yield
-50%-40%-30%-20%-10%0%med -4.6%Apr 25Jul 25Oct 25Jan 26Mar 26Jun 26Sep 26
SION Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-27.66%
Sep 26-30.25%
Aug 26-37%
Aug 26-41.05%
Aug 26-33.62%
Aug 26-4.25%
Jul 26-3.41%
Jul 26-3.51%
Jul 26-3.25%
Jul 26-3.55%
Jul 26-3.65%
Jun 26-3.81%
Jun 26-4.31%
Jun 26-4.47%
Jun 26-4.54%
May 26-3.75%
May 26-3.9%
May 26-3.99%
May 26-3.77%
May 26-4.26%
Apr 26-4.38%
Apr 26-3.83%
Apr 26-4.4%
Apr 26-4.12%
Mar 26-4.61%
Mar 26-4.58%
Mar 26-4.47%
Mar 26-4.64%
Feb 26-3.79%
Feb 26-3.91%
Feb 26-3.7%
Feb 26-3.84%
Jan 26-3.28%
Jan 26-3.27%
Jan 26-3.55%
Jan 26-3.53%
Jan 26-3.54%
Dec 25-3.17%
Dec 25-3.27%
Dec 25-3.24%
Dec 25-3.44%
Nov 25-3.18%
Nov 25-3.18%
Nov 25-3.75%
Nov 25-3.99%
Oct 25-3.8%
Oct 25-3.7%
Oct 25-4.54%
Oct 25-4.93%
Oct 25-4.83%
Sep 25-5.01%
Sep 25-6.27%
Sep 25-6.35%
Sep 25-6.04%
Aug 25-5.89%
Aug 25-5.95%
Aug 25-6.97%
Aug 25-7.19%
Aug 25-7.51%
Jul 25-6.65%
Jul 25-7.59%
Jul 25-6.22%
Jul 25-6%
Jun 25-8.02%
Jun 25-8.77%
Jun 25-7.76%
Jun 25-7.38%
May 25-9.28%
May 25-9.41%
May 25-8.91%
May 25-9.72%
May 25-8.81%
Apr 25-9.86%
Apr 25-10.81%
Apr 25-15.21%
Apr 25-12.01%
Mar 25-10.35%
Mar 25-8.74%
Mar 25-7.99%
Mar 25-7.36%
Feb 25-8%
Feb 25-5.57%
Feb 25-5.5%
Feb 25-4.4%
Price to Book
0246810med 4.98Jul 25Sep 25Dec 25Feb 26Apr 26Jul 26Sep 26
SION Price to Book by year
PeriodPrice to Book
Sep 261.33
Sep 261.22
Aug 261
Aug 260.9
Aug 261.1
Aug 268.67
Jul 267.35
Jul 267.12
Jul 267.7
Jul 267.06
Jul 266.86
Jun 266.57
Jun 265.81
Jun 265.6
Jun 265.51
May 266.67
May 266.41
May 266.27
May 265.76
May 265.1
Apr 264.96
Apr 265.67
Apr 264.93
Apr 265.27
Mar 264.71
Mar 264.74
Mar 264.86
Mar 264.68
Feb 265.05
Feb 264.91
Feb 265.19
Feb 264.99
Jan 265.84
Jan 265.86
Jan 265.41
Jan 265.43
Jan 265.42
Dec 256.04
Dec 255.86
Dec 255.91
Dec 255.57
Nov 256.02
Nov 256.04
Nov 255.11
Nov 254.8
Oct 255.01
Oct 255.14
Oct 254.19
Oct 253.86
Oct 253.94
Sep 253.8
Sep 253.04
Sep 252.99
Sep 253.15
Aug 253.23
Aug 253.2
Aug 252.73
Aug 252.21
Aug 252.12
Jul 252.39
Jul 252.1
Jul 252.56
Jul 252.66
Jun 251.99
Jun 251.82
Jun 252.05
Jun 252.16
May 251.72
Sionna Therapeutics, Inc.
SION
Stockpicker

Video analysis: SION

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SION

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

prnewswire.com · 10 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

globenewswire.com · 8 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

gurufocus.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

prnewswire.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).

SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm

globenewswire.com · 2 Sep 2026

SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sionna Therapeutics (SION) To Contact Him Directly To Discuss Their Options

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

globenewswire.com · 1 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SION INVESTIGATION: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

globenewswire.com · 31 Aug 2026

SION INVESTIGATION: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have any information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.

INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION

prnewswire.com · 27 Aug 2026

INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you any have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.